Market research
ALDX Aldeyra The
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 6.6
- Dividend yield
- Not available
- Beta
- 1.2
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US01438T1060
- Market cap
- 92M
- P/E ratio
- Not available
- Analyst target
- 6.6
- Dividend yield
- Not available
- Beta
- 1.2
About
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALDX discussion.
5 years, 4 months ago
Aldeyra Therapeutics, Inc is currently in a long term uptrend where the price is trading 2.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Aldeyra Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 14.2% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.0% to $-8M since the same quarter in the previous year.
Based on the above factors, Aldeyra Therapeutics, Inc gets an overall score of 4/5.